New research has developed a novel sensor device (microbiosensor) that alerts contact lens wearers when it is unsafe to put contact lenses in their eyes.
Uncategorized
Aerie Pharmaceuticals Initiates First Phase 3 Registration Trial of RoclatanTM
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that on September 18, dosing commenced of the first patients enrolled in Mercury 1, the Company’s first Phase 3 registration trial of RoclatanTM, a novel once-daily, quadruple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients
Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration
Status: Active, not recruiting,
Condition Summary: Macular Degeneration; Wet Macular Degeneration; Retinal Degeneration; Retinal Diseases; Eye Diseases
Uncategorized
Ophthalmology in need of antimicrobial stewardship
SAN DIEGO — Data recently presented at ICAAC 2015 suggest slower recovery and higher culture rates among microbial keratitis patients receiving antibiotic therapy. These outcomes indicate areas in which antibiotic stewardship may benefit ophthalmologic practice, according to Darlene Miller, DHSc, MPH, research associate professor of ophthalmology and scientific director of the Ocular Microbiology Laboratory at the University of Miami.
Anti-VEGF Therapy Before Steroids for Retinal Vein Occlusion
Aflibercept and ranibizumab should be the first-line options in the treatment of central retinal vein occlusion, according to one small study. Medscape Medical News
Tyrogenex Presents Final Results from Phase 1 Study of X-82 for Wet AMD at the 15th EURETINA Congress
NEEDHAM, Mass., & PALM BEACH GARDENS, Fla.–(BUSINESS WIRE)–Tyrogenex, focused on next-gen targeted therapeutics for ophthalmology, presented data from its phase 1 safety study of orally-administered X-82 in patients for wet AMD at EURETINA Congress.